BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 246 filers reported holding BIO-TECHNE CORP in Q3 2015. The put-call ratio across all filers is 1.94 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $91,885 | -13.8% | 1,349,853 | +3.4% | 0.22% | -10.3% |
| Q2 2023 | $106,606 | +17.1% | 1,305,973 | +6.4% | 0.24% | +9.5% |
| Q1 2023 | $91,056 | -9.8% | 1,227,334 | +0.8% | 0.22% | -14.9% |
| Q4 2022 | $100,894 | -99.9% | 1,217,348 | +309.4% | 0.26% | +12.5% |
| Q3 2022 | $84,452,000 | -19.3% | 297,366 | -1.6% | 0.23% | -16.8% |
| Q2 2022 | $104,712,000 | -13.3% | 302,079 | +8.3% | 0.28% | +18.2% |
| Q1 2022 | $120,824,000 | -5.1% | 279,014 | +13.1% | 0.24% | -4.1% |
| Q4 2021 | $127,344,000 | -13.8% | 246,673 | -19.1% | 0.25% | -18.0% |
| Q3 2021 | $147,777,000 | +19.3% | 304,965 | +10.9% | 0.30% | +19.0% |
| Q2 2021 | $123,845,000 | +194.0% | 275,052 | +149.4% | 0.25% | +171.0% |
| Q1 2021 | $42,123,000 | -26.7% | 110,292 | -39.0% | 0.09% | -30.1% |
| Q4 2020 | $57,428,000 | +57.6% | 180,848 | +22.9% | 0.13% | +37.1% |
| Q3 2020 | $36,444,000 | -0.7% | 147,110 | +5.8% | 0.10% | -11.8% |
| Q2 2020 | $36,719,000 | +4.3% | 139,052 | -25.1% | 0.11% | -13.4% |
| Q1 2020 | $35,189,000 | -10.9% | 185,575 | +3.1% | 0.13% | +13.4% |
| Q4 2019 | $39,508,000 | +29.2% | 179,982 | +15.1% | 0.11% | +17.9% |
| Q3 2019 | $30,584,000 | +53.4% | 156,305 | +63.5% | 0.10% | +55.7% |
| Q2 2019 | $19,934,000 | +176.7% | 95,614 | +163.6% | 0.06% | +165.2% |
| Q1 2019 | $7,204,000 | +90.0% | 36,279 | +38.4% | 0.02% | +64.3% |
| Q4 2018 | $3,792,000 | -27.6% | 26,204 | +2.1% | 0.01% | -12.5% |
| Q3 2018 | $5,240,000 | +313.6% | 25,674 | +199.9% | 0.02% | +300.0% |
| Q2 2018 | $1,267,000 | -1.2% | 8,561 | +0.8% | 0.00% | 0.0% |
| Q1 2018 | $1,283,000 | +21.0% | 8,493 | +3.8% | 0.00% | 0.0% |
| Q4 2017 | $1,060,000 | +6.2% | 8,179 | -1.0% | 0.00% | 0.0% |
| Q3 2017 | $998,000 | +8.8% | 8,260 | +5.8% | 0.00% | 0.0% |
| Q2 2017 | $917,000 | +22.9% | 7,810 | +6.5% | 0.00% | +33.3% |
| Q1 2017 | $746,000 | +8.4% | 7,330 | +9.6% | 0.00% | 0.0% |
| Q4 2016 | $688,000 | +2.5% | 6,690 | +9.1% | 0.00% | 0.0% |
| Q3 2016 | $671,000 | +5.7% | 6,130 | +9.1% | 0.00% | 0.0% |
| Q2 2016 | $635,000 | +33.4% | 5,620 | +11.5% | 0.00% | +50.0% |
| Q1 2016 | $476,000 | +16.4% | 5,040 | +10.8% | 0.00% | 0.0% |
| Q4 2015 | $409,000 | +7.9% | 4,550 | +11.0% | 0.00% | 0.0% |
| Q3 2015 | $379,000 | -7.1% | 4,100 | -1.2% | 0.00% | 0.0% |
| Q2 2015 | $408,000 | +25.2% | 4,150 | +27.7% | 0.00% | 0.0% |
| Q1 2015 | $326,000 | +12.4% | 3,250 | +3.2% | 0.00% | 0.0% |
| Q4 2014 | $290,000 | – | 3,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |